Tempus AI, Inc. (TEM) Earnings Call Transcript & Summary
November 4, 2025
Earnings Call Speaker Segments
Elizabeth Krutoholow
executiveThanks. Good afternoon, and welcome to the conference call for Tempus AI's third quarter of 2025. Results for the quarter that closed on September 30th, 2025 were issued by Tempus AI this afternoon. On our IR website, you can find the press release, a quarter overview, and our newest presentation. With me today from Tempus AI are Eric Lefkofsky, our Founder and CEO, and Jim Rogers, our CFO. Before starting, I want to note that management might make forward-looking statements on this call that carry risks and uncertainties which could lead to actual results differing materially. For a discussion of such risks, please see our 10-K and other later filings with the SEC. We will also discuss non-GAAP financial measures during the call, and these are not prepared in accordance with generally accepted accounting principles. Definitions of these non-GAAP financial measures, plus reconciliations to the most directly comparable GAAP financial measures, appear in our earnings release and can be found on our IR page. I'd now like to hand the call over to Eric.
Eric Lefkofsky
executiveThanks. The third quarter was strong across every part of our business. Genomics volume was extremely robust, delivering 33% growth overall; oncology rose 27%, while hereditary increased 37%. We anticipate hereditary growth to ease somewhat, though our current expectation is for it to land in the low- to mid-20s, rather than the mid- to high teens we previously guided to. Growth in genomics was broad-based. Truly, every one of our assays performed remarkably well, and given that MRD reimbursement remains on track plus our scheduled regulatory submission for the liquid biopsy xF later in the year, we anticipate further tailwind for that business, in both units and revenue. Our data licensing, or insights, business expanded 38% during the quarter, adding $150 million in total contract value — an exceptionally strong bookings quarter for us spanning multiple contracts that we called out in our letter. That comes on top of the multi-hundred-million-dollar foundation model deal we closed earlier in the year. Looking at bookings, our data licensing operation is simply delivering outstanding results. Combining genomics growth with growth in our data business let us produce positive Adjusted EBITDA for the first time this quarter, something we've pursued for 10 years and a significant milestone. That figure included several million dollars in extra expense from Paige, an acquisition we completed mid-quarter. Despite that, we achieved positive EBITDA, and absent Paige we would have been near $4 million in Adjusted EBITDA. The business is delivering precisely what we hoped for. For the full year, we now anticipate being slightly positive in Adjusted EBITDA, and that's including the several million dollars Paige dragged down. Overall, the business is performing well; we're expanding quickly, and we're controlling our costs to create leverage in the business, which is precisely where we want to be. With that, let's take some questions.
Ryan MacDonald
analystHello, and thank you for fielding my questions — congratulations on an excellent quarter. Eric, perhaps to begin regarding the genomics segment, clearly the oncology offerings keep delivering strong results, along with a sizable rise in testing volumes. Could you elaborate, or unpack a bit, what you would credit for such impressive strength in volume expansion? Are we beginning to observe a wider market and sector movement toward greater NGS testing, which is simply assisting in reaching additional patients who are undergoing sequencing? Or would you describe it as genuinely starting to reap rewards from operational adjustments and the sales footprint with the expanded offerings? Perhaps what portion reflects Tempus AI-driven achievement, so to speak, against wider sector and market tailwinds? Thank you.
Eric Lefkofsky
executiveYes. At a broad level, our achievement may differ somewhat from that of certain competitors. Allow me to discuss what I believe propels ours, and afterward we can address a few macro occurrences; regarding our achievement, it stems mostly from the reality that our Salesforce operates more effectively now compared to twelve months prior. We implemented major adjustments to our Salesforce upon introducing our MRD offerings. Whenever adjustments are made to Salesforces within this domain, disruption tends to follow. I believe folks don't truly grasp the extent of disruption created. Then everyone discusses the disruption once it has occurred. We definitely created some disruption, unintentionally so, and it required multiple quarters for us to resolve. Our sales team is presently properly trained and performing its duties, so we are gaining from that. The other factor is that our technology, which is very closely integrated and enables us to provide deeply contextualized, thorough outcomes to physicians, is gaining momentum as an increasing number of doctors desire us to supply results that assist them in treating patients more thoroughly and effectively. Thus we are gaining from those two developments. What I believe broadly people are gaining from. Certainly, testing volumes have remained robust as additional biomarkers get discovered. Individuals seek to ensure their patients undergo testing. Therefore I view that as a general tailwind for the field. Additionally, I believe certain firms may be gaining from having exclusively provided solid or exclusively provided liquid, so perhaps they now conduct more simultaneous testing, or perhaps some sequential testing occurs. We are not gaining nearly as much from that since we have maintained a comprehensive lineup for years at this point. Therefore, none of those sorts of one-time gains are visible to us, meaning that our unit growth appears, at least in our view, quite robust and lasting, because we aren't being artificially buoyed by any type of one-time advantage in either our solid or liquid assays that accounts for most of that increase.
Mark Massaro
analystHi everyone, and nice work on the quarter. Eric, I'd like to ask you something—since there's clearly plenty of curiosity not just around AI and big data, obviously, but also a great deal of curiosity about MRD testing. So I was hoping you might share where things stand regarding your strategy for launching MRD into the clinic, given that Personalis is a partner of yours. What I'm wondering is whether your team has been trained for this. My understanding is that they have. Could you also help us understand how quickly you might move, if reimbursement arrives within the next several weeks or months? In what way do you intend to take advantage of your sizable sales organization and bring this to market in competition with a few other rather notable labs operating here?
Eric Lefkofsky
executiveSure. At a broad level, to start with, when you're seeing roughly 27% unit growth, setting the hereditary side apart, the unit growth we're achieving is something we view as pretty strong. As we've previously stated, and as we actually pointed out in our letter, our expectation is roughly 25% growth across the following three years, which represents a rather remarkable level of expansion. Considering how big we are and our scale, we don't wish to expand 40% in this quarter and afterward 20% in Q1 of the following year; what we're after is durable unit growth and revenue growth over the long haul, and we believe we're positioned quite well to achieve that. So I wouldn't anticipate that once MRD reimbursement comes through, we'd instantly attempt to push as many tests into the market as possible, whatever that might entail, and sort of artificially inflate our growth rates. My expectation is that we'd increase that incrementally each quarter more aggressively as reimbursement renders it more affordable. That's what we'll do. Our portfolio is quite strong, covering both naive and informed products across CRC, breast, lung, and IO; plus we have a large number of—which we also mention in our letter—a large number of fresh studies underway featuring an even more sensitive iteration of our tumor-naive assay. So we're putting substantial investment into this area, and so is Personalis; and our collection of tumor-naive and tumor-informed MRD assays is genuinely solid. And we will definitely make use of our sizable sales force. Beyond that, a portion of that sales force is thoroughly trained in MRD, and we'll keep increasing that. I wouldn't anticipate anything excessive from us when it comes to sales force investment, nor anything excessive regarding growth, yet it will definitely be beneficial; it's among the tailwind factors we have that we think can drive us toward 25% growth in this area over the next three years. And when you consider how big our operation is and then project forward 36 months, by that time you're talking about a genomics business in oncology that's quite substantial.
Dan Brennan
analystGreat, thank you. I appreciate you taking the questions, and congratulations on the quarter. Maybe we could start with the new contracts, Eric. My understanding is that the company hasn't been very forthcoming about new bookings — you had that PathosAI deal earlier this year, but I believe it's only been discussed annually. So could you walk us through the $150 million? There were plenty of specifics in the press release regarding the various customers. But could you give us a bit more color on why you decided to disclose this, and why these particular deals came together at this point? Since you're walking us through the bookings recap, perhaps you could bring us up to speed on the current state of the backlog. Any additional detail on how that's trending would help, and also whether these were anticipated. Did you think they'd land during this year, or the next one? Whatever further insight you can offer would be useful, given that this stood out as a fairly unusual item to flag in the quarter. Appreciate it.
Eric Lefkofsky
executiveSure. To begin with, in earlier quarters we've made an effort to give a sense of how large a few of these data agreements are. This isn't the first instance where we've highlighted deal size either by customer or by dollar figure—we did so previously when discussing the AZ PathosAI agreement, which included several hundred million dollars in extra data licensing. When something reaches a threshold where we believe it deserves attention, we attempt to flag it. Put differently, when contracts are just being signed at a typical pace, we may simply mention one or two of them. But if we believe a group of deals fits together in a manner that merits being pointed out and emphasized, that's when we emphasize it. You can't really pinpoint why this particular quarter looked the way it did compared to others. Getting into a pattern where each quarter we're saying, "Well, bookings came in at 56 million, or 152 million, or whatever, 212," isn't something we want to do, since that just adds confusion — as though that figure automatically shows up as revenue the following quarter. It doesn't work that way, because these bookings, just like every booking we take, stretch across multiple years. So signing $150 million worth of data licensing right now doesn't translate into my revenue rising by 150 million next quarter or next year. Deals like these usually span several years, so we make an effort to avoid creating chaos. Our total contract value is sitting in a really strong position. We're going to share that figure when the year wraps up. We committed to providing it on a yearly basis, but obviously the world already knows about over $350 million in bookings from just two data points. So it's safe to say the actual total is considerably higher than that, which puts us in a very strong position. When we do eventually report it annually, it's going to be an impressive number. So it's delivering exactly what you'd want it to deliver, which is continued growth. And at this moment, despite how large we've become, we're experiencing genuinely powerful momentum in securing big or major data licensing deals; four of those were called out in this release. A number of those involve parties taking licenses to our analytic software Lens. A number involve parties taking licenses to data libraries or asking us to obtain more data. But these are fairly ordinary sorts of agreements, where people come to us more and more because our data offering is simply very hard to match. And that shows up in the size of our business, the expansion of the business compared with the peer group we measure against, all of whom are very well-established organizations. I mean, if you consider whom we go up against in diagnostics, these aren't thinly capitalized organizations; they're large organizations; they're richly funded. Typically they've operated far longer than we have. To whatever degree they ought to possess data, they ought to possess enormous amounts of data. So when you compare our data business expanding and theirs, what sets us apart is simply that we hold a one-of-a-kind data asset. We've put money into a huge number of offerings built on that, among them proprietary software along with tools and technology. It connects with those who take licenses to our data. They take licenses to greater amounts of our data routinely. And so we're simply moving further and further away from anyone else we're aware of in the oncology data arena. And I detect no indication that this is tapering off.
Casey Woodring
analystThanks for fielding our questions. First, congratulations on yet another solid quarter for core oncology volumes. A competitor recently entered the market and likewise posted robust liquid therapy selection volumes. So I'm curious whether you're observing a comparable acceleration in xF and a broader market movement toward liquid. Then, as a follow-up, you mentioned intentions to file xF for FDA approval during 4Q, with a complete PMA submission for xR coming afterward. Assuming those tests secure FDA approval, I take it they would qualify for ADLT status. Could you just talk us through how you see the potential upside playing out over the coming year for the Medicare list price on those tests, and what might serve as a reasonable benchmark for the price you'll be aiming to secure for them? Thanks.
Eric Lefkofsky
executiveSure. So, one thing that sets Tempus AI apart is that we're now viewed as a formidable player essentially across the whole continuum. When someone is at risk, we're a leader in hereditary profiling. When it comes to picking a therapy, whether that's solid tumor or liquid biopsy, we're a leader there too. And with MRD and monitoring, we now have a compelling offering as well. As a result, people tend to view us from an end-to-end perspective. What's fascinating is that we're likely well positioned to detect some of these major changes, and we didn't detect them. Our solid tumor assay grew really strongly. Our liquid business grew really strongly. Nothing jumped out at us as a basic move away from solid toward liquid. Both certainly grew really strongly from the prior period to this one. Having said that, I'd acknowledge that with particular trials, SERENA 6 being one example, where you may conduct liquid testing more repeatedly, I could envision our liquid portfolio gaining some extra volume down the road that we and others might gain from. Right now, though, I wouldn't call it a dramatic change. That said, I still believe solid's potential is strong as an increasing number of physicians prescribe it, and liquid may be even more promising, since you'll gain from a portion of that serial testing.
Jim Rogers
executiveOkay, Casey, on the reimbursement side. Like we said before, the longer-term favorable forces remain intact. With xT and CDX, we wrapped up the quarter with about 30% of volume already transitioned. What we intend to do now is move most of that over to the FDA-approved or ADLT version across 2026. You pointed out as well in that letter that xF is getting submitted to the FDA prior to the end of this year. Obviously, that takes a long time, so we're not able to speak to particular reimbursement amounts, though ADLT typically provides some benefit compared with where we are now. Then xR follows that. From where we sit, total reimbursement came to an average of $1,600 during the third quarter, an increase of roughly $20 from the prior quarter, but it's still well short of parity with our peers. That figure sits alongside the broader reimbursement picture, including the $212 million we've discussed. So through these initiatives and regulatory submissions, that ought to help us close that distance.
Colleen Babington
analystHi there. Thanks for taking the question. Colleen here, filling in for Doug. We've got something to ask regarding Ambry. Things keep going nicely for Ambry, and results are beating what was expected. Our understanding is that during the prior quarter, roughly half the growth came from picking up share, with the other half coming from natural expansion. Could you shed light on what that split looked like in the current quarter? In addition, one of the competitors said yesterday evening that its volumes in hereditary cancer rose at a low double-digit pace during Q3. So should industry growth in the low double-digit range be treated as a sensible baseline? Given that backdrop, could you explain more about how Ambry's growth stacks up against the wider market? And last, again on Ambry, could you spell out the panel mix — meaning bigger panels such as Cancer Next versus the more narrowly focused ones — and what that means for how we ought to view ASPs moving forward?
Jim Rogers
executiveYeah. I'll kick things off, then Eric may want to jump in; so much like the prior quarter, roughly 50% of the gain is being generated by share gains. As the letter points out, we anticipate that will ease in Q4; and so a low- to mid-20s figure strikes us as the more probable outcome versus where things are trending right now. Clearly, when it comes to competitors, there's no way for us to address the share gains or growth rates others are seeing. But Ambry keeps performing strongly, whether through attracting new customers who used to work with our competitors, or through further growing share of wallet among accounts we already have. Eric, is there anything you'd like to add?
Eric Lefkofsky
executiveYes. So when it comes to the market as a whole, my view is that this space is performing far better than most anticipated. We've been saying this across the past few quarterly calls. So where folks previously assumed this area would see flat or weak growth, now you're hearing them say, "Oh yeah, we're expanding at a low double-digit rate," and I'd agree that's likely accurate. Our hereditary business, we believe, will expand somewhere in the low to mid-20s, which puts it well above that overall figure because we currently offer what's essentially the gold standard assays in that market. Now, it's certainly possible you'll witness a growth rate hitting the high 20s or low 30s. That could definitely occur, whether during Q4, Q1, or Q2; and as we've always done, we'll point out that I wouldn't anticipate that persisting as a long-term pattern. Our view for the long term is low to mid-20s. That strikes us as quite healthy and within reach. And that's the state of that business. Would you like to address the ASP part first?
Jim Rogers
executiveRight. Regarding how the assays break down, we don’t give detail at the assay level. Over the past few quarters, ASPs have stayed fairly steady, down somewhat compared with a year earlier, as one of our bigger payers reworked contracts, but on the whole, they’ve been pretty stable in hereditary. The one factor that will affect ASPs is that the rare business remains a comparatively small piece of total testing for Ambry, yet it carries a higher ASP. So as that keeps scaling, it will also have some effect on ASPs.
Eric Lefkofsky
executiveJust to jump in on that for a second. Rare companies are not plentiful. I mean, at this point we've reached a certain scale. A handful of others exist. GeneDx, of course, is a well-known one, but there aren't many. My belief is that over the coming 12 to 18 months, we will gain genuine ground toward becoming a major player in that area.
Michael Ryskin
analystThanks for taking my question, guys. I'd like to build on the previous one about Ambry, but perhaps connect it to the broader picture. If I look at the guidance, it appears you raised the full-year outlook. In effect, that reflects the third-quarter beat; however, based on what you just said regarding Ambry, if the growth rate moves from the mid-to-high teens into the low-to-mid 20s, our calculations suggest roughly $20 million in additional revenue for the entire year. If anything is counterbalancing that—whether you're pulling something from the older genomics operation, or perhaps from data and services—it would help if you described that bridge a bit and explained how it adds up across the whole year. Thank you.
Jim Rogers
executiveSure; I'll begin, and Eric may add something after. Ambry's Q3 expansion came in at roughly 32%. That means we expect a sequential decline from 32% as we move into Q4. So Q4 won't be higher.
Eric Lefkofsky
executiveYet let's go ahead and suppose that anyway. As you're saying, suppose Ambry is beating expectations by some figure — say $15 million to $20 million annually — and in Q4 that could translate into a $5 million gain, our stance remains exactly what it has always been. We look at it and tell ourselves, "A beat plus a raise — fantastic." Still, there's no reason to race ahead of ourselves. Nothing good comes from it. Our aim is to sit in a spot where we keep surpassing what's expected, time after time, and there's simply no cause to push expectations up on purpose, particularly given that our underlying business is expanding at 30%. Had growth been sitting at 4%, maybe we'd be thinking, "Oh man, we have to lift expectations." Yet our business is expanding at a genuinely robust pace, and what we want is to keep everyone focused on the fact that whether Q4 brings 31% growth, or 29%, or 30%, none of that is what counts. The real question is whether we can produce 25% growth — not merely across the coming three years, but across the coming 10 years. Should we manage that, this becomes an extremely, extremely large business. So our whole structure is built for long-term growth rather than the short term. That's the way we guide.
Analyst
analystHello; Ricky here, filling in for Subbu. We appreciate you answering our question. You touched on this somewhat in the letter, but might you provide any new details regarding the foundation model collaboration with AstraZeneca and PathosAI, and perhaps what upcoming milestones we ought to watch for? Also, is there any upside you might mention that stems from the Paige acquisition in relation to the foundation model efforts? Thank you.
Eric Lefkofsky
executiveYes. The foundation model is currently wrapping up its pretraining stage. Things are going extraordinarily well regarding. You take all those smaller models, including individual ones plus multimodal ones, and evaluate their performance, whether they are predictive, and you compare them against those typical benchmarks such as C-Index to gauge their results. Everything is progressing remarkably well. The teams are feeling terrific. We are essentially moving into the stage involving large compute across the coming months; after that concludes, post-training starts later in this year, roughly early 2026, and we anticipate having the initial iterations of the model during Q1; overall, the team is extremely pleased with our advancement on all fronts, so there are no warning signs whatsoever. And I would. We are currently in the process of obtaining extra GPU capacity. We believe this is simply. A benefit that we possess, and we intend to embrace it and commit further. And we will tackle our, when you examine, and we point this out within the letter, when you examine Tempus AI compared with other firms, we will appear, seem, and come across as a tech company. In numerous respects, such as the lines of code that we produce, the sum of money we allocate toward cloud and compute, the count of software engineers that we employ. And we exist in a time where AI is arriving, and we find ourselves ideally positioned, in our view. We are putting substantial resources into that. And rather than easing off the accelerator, I believe we will keep pushing onward. Paige is excellent because they were pursuing their own foundation model initiatives. Within digital pathology, they possess an outstanding team and have achieved genuinely compelling advancements there. Those groups are now linked. They are currently integrated into our foundation model team; we are combining some of that information and attempting to grasp the insights. Thus, a considerable amount of positive momentum emerges from that. And we are eager to discover where it leads.
David Westenberg
analystHi there, and thanks for taking my question. I want to zoom in a bit more on the longer horizon. By and large, the way reimbursement works — CPT codes and so on — has mostly been set up to pay for the bench work you perform. At this point you've built up a substantial amount of data, plus some very strong analysis and interpretation. Do you think the healthcare system can realistically begin paying for the hard parts of interpreting and analyzing data? And do you think there remains a meaningful distinction, or maybe a big one, between what happens at the bench — say, error correction — and the rest? Thank you.
Eric Lefkofsky
executiveYeah. So, look, when we look at this business, and if you take the guidance we've given — the longer-range outlook of 25% growth across the coming three years — that outlook was constructed almost completely around the expansion we can observe in diagnostics and in data. Those are large operations, dependable, running at scale, with attractive growth rates and attractive margins. We know them well. When it comes to certain algorithms we've brought to market, forecasting their growth rate is extremely difficult for us. Essentially, as you put it, this dry lab CPT code area — pinning down the revenue tied to it is hard, since right now it isn't reimbursed well, or possibly not at all. Our view is that eventually this will shift; eventually it must shift, otherwise the healthcare system in this country risks serious trouble; we simply cannot sustain $5.7 trillion a year expanding at 7.5%. The sole answer to this challenge involves some degree of intelligence — call it AI — that lets us see where errors happen, where waste happens, where mistakes happen, and where we can act predictively and preventively; somebody will have to pay for that, or scaling won't happen. Once payment exists, Tempus AI holds a genuinely unique position, since we already have so much of this. We put substantial money into our results, and even with positive EBITDA, we're producing a huge number of algorithms. I mean, a lot. We have algorithms spanning digital pathology, radiology, cardiology, neuropsych, oncology, across the whole spectrum; so once these get paid for, we can roll them out through the more than 5,000 hospitals tied into our ecosystem very fast. And a lot of these already need to be approved. So our expectation is that our reimbursement path would move very quickly if such a path exists; and I've noted this before, if Tempus AI ever gets its NVIDIA moment, or whatever that moment turns out to be, it will be because one of these starts getting paid for, or two or three of them, and then they scale fast. In the wet lab, revenue growth might take you from 100 million up to 150 million. That's an extremely tough climb. Yet with algo, you can jump from 100 million in revenue to a billion in revenue overnight, since what you're distributing is zeros and ones rather than needing to gather biospecimens, perform a test, and then deliver it — the scaling works in a completely different way. So my hope is that they receive payment for it. I don't see another route out of this situation, and our position is strong.
Mark Schappel
analystHello. I appreciate you taking my question. Eric, I'd like to ask about Paige AI. Beyond the AI pathology applications they offer, I understand they also deliver certain synergies and advantages to your genomic diagnostics operation. Could you share a bit more detail regarding how Paige AI truly supplements or interacts with your diagnostics business?
Eric Lefkofsky
executiveYes. What I'd say is it's going to function wonderfully. Clearly, we only just bought Paige AI quite recently. So several of these items are in the process of being combined right now. But let me offer a single illustration of how digital pathology may boost sequencing; so to begin with, in a certain share of cases, sequencing fails; it simply fails. You cannot sequence the patient. Granted, that's a small share, yet it genuinely happens; people refer to it as QNS. No results get reported. Or in a certain share of cases, you lack sufficient material to conduct sequencing at all. You simply don't have adequate material, with a tumor percentage high enough, to sequence the patient at all. When that happens, at present, we tell a doctor, "There's nothing I can do for you. I have no result to give." Yet in a scenario where you possess these digital pathology algorithms available for use that are capable of forecasting the most frequent mutations that sequencing might reveal, and Paige AI currently has several of these underway with additional ones on the way, one cleared by the FDA, with others before the FDA, you can essentially give results back to physicians even in cases where NGS doesn't succeed. In the same way, you can picture a scenario where a specific quantity of results is truly essential to obtain extremely fast. Take, for instance, a patient with non-small cell lung cancer; you need to find out whether their EGFR is mutated within one or two days. Thus another advantage of bringing these together is that we'll be capable of producing a certain number of predictions extremely rapidly. So we have long believed that the victorious solution here came via this sort of multimodal strategy of examining all the data that can be produced for a patient and generating the finest data-driven insights as quickly as possible; and typically those are never driven by a single data modality. So we aim to exist in a scenario where we're just as proficient at producing molecular data as we are at producing digitized pathology data or interpreting a CT scan, an MRI, or mammography. And when you examine our investments, we direct our investments in that direction; and I believe eventually, comparable to how, if you had looked at Amazon, say, 20 years back, you might have remarked, "Oh, who cares. They ship books." Or perhaps they ship books and consumer electronics, and they aren't significantly superior to eBay. Yet if you begin to jump ahead 5 years, 10 years, you can perceive the differentiation through Amazon's capacity to essentially provide you with anything you desire instantaneously. This is a result of what they put into both the depth of their product and how quickly they could distribute it. We're doing something comparable — or at minimum, the equivalent of those comparable investments within our current portfolio.
Dan Arias
analystYeah. Hi, everyone. Appreciate you letting us ask a few things here. Perhaps one about MRD. You've made it quite plain that there aren't plans in place to pour loads of cash into large trials. Even so, it certainly sounds as though investment is happening in that area. So if R&D is part of that, should we be watching for any data in the coming year? It really looks like a whole wave of highly sensitive assays is heading to market across the next 12-plus months. So I simply want to confirm we're tracking the correct items and any Tempus AI updates within that conversation.
Eric Lefkofsky
executiveYeah. What I'd say is we release — and I believe this gets mentioned in our investor deck — we release publications, posters, presentations all the time. The volume is honestly wild. I was just glancing at the SITC press release. There are roughly seven papers in it or something like that. So we're putting this material out quite consistently. Regarding large trials, I think we noted in the letter that on the tumor naive side, CRC is where we are today. A non-small cell lung cancer trial is underway right now; we probably will circle back and revisit a portion of our CRC efforts. And my guess is you'll see data emerge regarding each of those in the coming year. Past that, we could spill into early 2027 when it comes to additional disease areas or additional disease indications we enter. Yet we anticipate having genuinely compelling data on the market next year from our tumor naive assay in lung as well as CRC. And we think we're achieving metrics that are simply extremely strong on the tumor naive side, which let us essentially compete directly with certain tumor-informed players thanks to enhancements we've developed in-house — we have 400 PhDs working here; so it's a reasonably big and skilled technical group. As for tumor-informed, I'll let Personalis give you their own roadmap regarding what's ahead and which trials they're running. But they're also putting in, in my view, a pretty substantial amount.
Elizabeth Krutoholow
executiveOkay, I appreciate it. Thanks to everyone for being here with us at this time. We're eager to bring you another update when the following quarter arrives.
Operator
operatorThis concludes today's conference call. Give me an hour to disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Tempus AI, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Tempus AI, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Tempus AI, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.